A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND The DoMore-v1-CRC marker was recently developed using deep learning and conventional haematoxylin and eosin-stained tissue sections, and was observed to outperform established molecular and morphological markers of patient outcome after primary colorectal cancer resection. The aim of the present study was to develop a clinical decision support system based on DoMore-v1-CRC and pathological staging markers to facilitate individualised selection of adjuvant treatment. METHODS We estimated cancer-specific survival in subgroups formed by pathological tumour stage (pT<4 or pT4), pathological nodal stage (pN0, pN1, or pN2), number of lymph nodes sampled (≤12 or >12) if not pN2, and DoMore-v1-CRC classification (good, uncertain, or poor prognosis) in 997 patients with stage II or III colorectal cancer considered to have no residual tumour (R0) from two community-based cohorts in Norway and the UK, and used these data to define three risk groups. An external cohort of 1075 patients with stage II or III R0 colorectal cancer from the QUASAR 2 trial was used for validation; these patients were treated with single-agent capecitabine. The proposed risk stratification system was evaluated using Cox regression analysis. We similarly evaluated a risk stratification system intended to reflect current guidelines and clinical practice. The primary outcome was cancer-specific survival. FINDINGS The new risk stratification system provided a hazard ratio of 10·71 (95% CI 6·39-17·93; p<0·0001) for high-risk versus low-risk patients and 3·06 (1·73-5·42; p=0·0001) for intermediate versus low risk in the primary analysis of the validation cohort. Estimated 3-year cancer-specific survival was 97·2% (95% CI 95·1-98·4; n=445 [41%]) for the low-risk group, 94·8% (91·7-96·7; n=339 [32%]) for the intermediate-risk group, and 77·6% (72·1-82·1; n=291 [27%]) for the high-risk group. The guideline-based risk grouping was observed to be less prognostic and informative (the low-risk group comprised only 142 [13%] of the 1075 patients). INTERPRETATION Integrating DoMore-v1-CRC and pathological staging markers provided a clinical decision support system that risk stratifies more accurately than its constituent elements, and identifies substantially more patients with stage II and III colorectal cancer with similarly good prognosis as the low-risk group in current guidelines. Avoiding adjuvant chemotherapy in these patients might be safe, and could reduce morbidity, mortality, and treatment costs. FUNDING The Research Council of Norway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moons, K. G. M., Altman, D. G., Reitsma, J. B., Ioannidis, J. P. A., Macaskill, P., Steyerberg, E. W., Vickers, A. J., Ransohoff, D. F., & Collins, G. S. (2015) · Annals of Internal Medicine · doi:10.7326/m14-0698 · Cited by 5,147
Kather, J. N., Pearson, A. T., Halama, N., Jäger, D., Krause, J., Loosen, S. H., Marx, A., Boor, P., Tacke, F., Neumann, U. P., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0462-y · Cited by 1,458
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Argilés, G., Tabernero, J., Labianca, R., Hochhauser, D., Salazar, R., Iveson, T., Laurent-Puig, P., Quirke, P., Yoshino, T., Taieb, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.022 · Cited by 1,375
Duration of adjuvant chemotherapy for stage III colon cancer
Grothey, A., Sobrero, A. F., Shields, A. F., Yoshino, T., Paul, J., Taieb, J., Souglakos, J., Shi, Q., Kerr, R., Labianca, R., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713709 · Cited by 1,092
Self-citationAndré, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., Scriva, A., Hickish, T., Tabernero, J., Van Laethem, J. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4238 · Cited by 683
Deep learning for prediction of colorectal cancer outcome: a discovery and validation study
Skrede, O.-J., De Raedt, S., Kleppe, A., Hveem, T. S., Liestøl, K., Maddison, J., Askautrud, H. A., Pradhan, M., Nesheim, J. A., Albregtsen, F., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(19)32998-8 · Cited by 627
Self-citationYamashita, R., Long, J., Longacre, T., Peng, L., Berry, G., Martin, B., Higgins, J., Rubin, D. L., & Shen, J. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30535-0 · Cited by 391
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update
Baxter, N. N., Kennedy, E. B., Bergsland, E., Berlin, J., George, T. J., Gill, S., Gold, P. J., Hantel, A., Jones, L., Lieu, C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02538 · Cited by 367
Echle, A., Ghaffari Laleh, N., Quirke, P., Grabsch, H. I., Muti, H. S., Saldanha, O. L., Brockmoeller, S. F., van den Brandt, P. A., Hutchins, G. G. A., Richman, S. D., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100400 · Cited by 111
Cited by
Artificial intelligence for digital and computational pathology
Song, A. H., Jaume, G., Williamson, D. F. K., Lu, M. Y., Vaidya, A., Miller, T. R., & Mahmood, F. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00096-8 · Cited by 356
Wagner, S. J., Reisenbüchler, D., West, N. P., Niehues, J. M., Zhu, J., Foersch, S., Veldhuizen, G. P., Quirke, P., Grabsch, H. I., van den Brandt, P. A., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.08.002 · Cited by 275
Self-citationHarnessing the Power of Clinical Decision Support Systems: Challenges and Opportunities
Chen, Z., Liang, N., Zhang, H., Li, H., Yang, Y., Zong, X., Chen, Y., Wang, Y., & Shi, N. (2023) · Open Heart · doi:10.1136/openhrt-2023-002432 · Cited by 244
Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment
Zhang, C., Xu, J., Tang, R., Yang, J., Wang, W., Yu, X., & Shi, S. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01514-5 · Cited by 148
End-to-end prognostication in colorectal cancer by deep learning: a retrospective, multicentre study
Jiang, X., Hoffmeister, M., Brenner, H., Muti, H. S., Yuan, T., Foersch, S., West, N. P., Brobeil, A., Jonnagaddala, J., Hawkins, N., et al. (2024) · The Lancet Digital Health · doi:10.1016/s2589-7500(23)00208-x · Cited by 108
Metadata
- Authors
- Kleppe, A., Skrede, O.-J., De Raedt, S., Hveem, T. S., Askautrud, H. A., Jacobsen, J. E., Church, D. N., Nesbakken, A., Shepherd, N. A., Novelli, M., Kerr, R., Liestøl, K., Kerr, D. J., & Danielsen, H. E.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 23
- Issue
- 9
- Pages
- 1221-1232
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W4291008673
- Cited by
- 91
- References
- 9
- FWCI
- 7.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study. https://app.cochat.ai/papers/10.1016/s1470-2045(22)00391-6
- The paper
- Kleppe, A., Skrede, O.-J., De Raedt, S., Hveem, T. S., Askautrud, H. A., Jacobsen, J. E., Church, D. N., Nesbakken, A., Shepherd, N. A., Novelli, M., Kerr, R., Liestøl, K., Kerr, D. J., & Danielsen, H. E. (2022). A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(22)00391-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.